Ironwood Pharma (NASDAQ:IRWD) reported Q4 EPS of $0.27, $0.02 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $107.2 million versus the consensus estimate of $114.93 million.
Ironwood Pharma (NASDAQ:IRWD) reported Q4 EPS of $0.27, $0.02 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $107.2 million versus the consensus estimate of $114.93 million.